Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -15636.44% is 36% below its 5-year average of -11498.46%, near the high end of its 5-year range (-2094916.67%–85.12%).
40.27% below its 12-month average of -11147.68%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1085.32%.
EBITDA MARGIN
-15636.44%
EBITDA MARGIN AVG TTM
-11147.68%
EBITDA MARGIN AVG 3Y
-12114.53%
EBITDA MARGIN AVG 5Y
-11498.46%
EBITDA MARGIN AVG 10Y
-13263.62%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-40.27%
CURRENT VS 3Y AVG
-29.07%
CURRENT VS 5Y AVG
-35.99%
CURRENT VS 10Y AVG
-17.89%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
CRISPR Therapeutics AG
Market Cap
$5.35B
EBITDA Margin
-15636.44%
TTM Avg
-11147.68%
3Y Avg
-12114.53%
5Y Avg
-11498.46%
Market Cap
$5.10B
EBITDA Margin
21.06%
TTM Avg
20.50%
3Y Avg
18.63%
5Y Avg
16.67%
Market Cap
$5.61B
EBITDA Margin
-395.82%
TTM Avg
-536.17%
3Y Avg
-471.62%
5Y Avg
-471.62%
Market Cap
$6.47B
EBITDA Margin
6.82%
TTM Avg
6.08%
3Y Avg
-0.44%
5Y Avg
-8.67%
Market Cap
$6.63B
EBITDA Margin
15.93%
TTM Avg
16.80%
3Y Avg
17.55%
5Y Avg
18.41%
Market Cap
$2.76B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$8.02B
EBITDA Margin
-3.14%
TTM Avg
-1.08%
3Y Avg
-5.02%
5Y Avg
-19.32%
Market Cap
$2.52B
EBITDA Margin
-270.04%
TTM Avg
-444.88%
3Y Avg
-365.27%
5Y Avg
-89273.54%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | $5.35B | -15636.44% | -11147.68% | -12114.53% | -11498.46% |
| Doximity, Inc. (DOCS)vs › | $5.22B | 35.56% | 38.69% | 36.58% | 34.55% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.10B | 21.06% | 20.50% | 18.63% | 16.67% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.61B | -395.82% | -536.17% | -471.62% | -471.62% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.47B | 6.82% | 6.08% | -0.44% | -8.67% |
| Chemed Corporation (CHE)vs › | $6.63B | 15.93% | 16.80% | 17.55% | 18.41% |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 22.42% | 17.70% | -0.76% | -37.34% |
| Oscar Health, Inc. (OSCR)vs › | $8.02B | -3.14% | -1.08% | -5.02% | -19.32% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | -270.04% | -444.88% | -365.27% | -89273.54% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | -755.79% | -753.93% | -709.93% | -1157.85% |
Gross Margin
-6537.0%
EBITDA Margin
-15636.4%
Operating Margin
-16191.4%
Net Margin
-3368.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1085.32% |
| 2026-03-31 | -8637.11% |
| 2025-12-31 | -17257.29% |
| 2025-09-30 | -14356.13% |
| 2025-06-30 | -14402.58% |
| 2025-03-31 | -16611.33% |
| 2024-12-31 | -170.70% |
| 2024-09-30 | -17506.81% |
| 2024-06-30 | -28320.12% |
| 2024-03-31 | -26935.32% |
| 2023-12-31 | 37.24% |
| 2023-06-30 | -128.95% |
| 2023-03-31 | -59.44% |
| 2022-12-31 | -2094916.67% |
| 2022-09-30 | -188691.49% |
| 2022-06-30 | -111386.71% |
| 2022-03-31 | -95467.98% |
| 2021-12-31 | -1080.99% |
| 2021-09-30 | -37545.59% |
| 2021-06-30 | 85.12% |
| 2021-03-31 | -55360.40% |
| 2020-12-31 | -28431.08% |
| 2020-09-30 | -60854.05% |
| 2020-06-30 | -178402.27% |
| 2020-03-31 | -45538.22% |
| 2019-12-31 | 16.12% |
| 2019-09-30 | 66.27% |
| 2019-06-30 | -16913.52% |
| 2019-03-31 | -14515.55% |
| 2018-12-31 | -38506.96% |
| 2018-09-30 | -8623.27% |
| 2018-06-30 | -3347.52% |
| 2018-03-31 | -1927.17% |
| 2017-12-31 | 5.50% |
| 2017-09-30 | -954.25% |
| 2017-06-30 | -575.10% |
| 2017-03-31 | -740.81% |
| 2016-12-31 | -1062.20% |
| 2016-09-30 | -927.95% |
| 2016-06-30 | -2061.26% |
| 2016-03-31 | -2425.63% |
| 2015-12-31 | -4901.62% |
